How does Jynarque (tolvaptan) work in the body?
Jynarque’s active ingredient, tolvaptan, is a vasopressin (antidiuretic hormone) receptor antagonist. It blocks vasopressin signaling at the V2 receptors in the kidney collecting ducts, which reduces water reabsorption. The result is increased excretion of free water (aquaresis) rather than salt wasting. [1]
What does blocking V2 receptors change in kidney fluid handling?
By inhibiting V2 receptor activity in the collecting ducts, tolvaptan prevents vasopressin from promoting water transport through aquaporin-2 channels. With that water-transport pathway suppressed, more water is delivered into the urine, lowering water retention and helping correct hyponatremia-related issues tied to excess antidiuretic hormone effect. [1]
What is the link between Jynarque’s action and polycystic kidney disease (ADPKD)?
In ADPKD, vasopressin signaling (through V2 receptors) is associated with increased cyst growth. Tolvaptan antagonizes that pathway, which reduces downstream processes believed to contribute to cyst expansion, based on the drug’s vasopressin V2 blockade mechanism. [1]
What happens if patients stop Jynarque or miss doses?
Because the drug’s effect depends on ongoing vasopressin V2 blockade, stopping or missing doses allows vasopressin signaling to resume. That can reduce aquaresis (less free-water clearance), which may lead to a return toward baseline fluid balance and, depending on the patient’s condition, loss of the intended therapeutic effect. [1]
Common practical effects from the mechanism (why patients urinate more)
Blocking vasopressin V2 signaling increases free-water loss, so patients typically experience increased urination and thirst as a direct pharmacologic consequence of aquaresis. This is the main mechanism-driven reason Jynarque is managed with careful fluid intake to reduce the risk of dehydration or overly concentrated/overly diluted electrolytes. [1]
Sources
- Drug label information on Jynarque (tolvaptan) mechanism: DrugPatentWatch.com – https://www.drugpatentwatch.com/p/jynarque-tolvaptan/